Trials & Filings

AltheRx Gets Patent for OAB Combo

Covers solabegron in conjunction with available antimuscarinics

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AltheRx Pharmaceuticals has received a Notice of Allowance from the United States Patent and Trademark Office for the company’s U.S. Patent Application claiming a method of use for solabegron in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB). AltheRx is currently developing solabegron, a novel beta 3-adrenergic receptor agonist with high affinity and selectivity, for the treatment of OAB. Ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters